Evoke, Eversana: Improvement in Patient Outcomes for GLP-1 users in Diabetic Gastroparesis

 Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in All Cause Emergency Department Visits (-91%, p=0.001), All Cause Office Visits (-41%, p=0.027) and All Cause Hospital Outpatient Visits (-89%, p=0.032) within 6-month index period

Data presented at American College of Gastroenterology (ACG) 2024; the submission garnered both the Presidential Poster Award as one of the top 5% of data accepted to the conference and selected as the Outstanding Research Award in the Stomach Category

First study to show Gimoti’s potential as supportive care for GLP-1 therapy

https://www.globenewswire.com/news-release/2024/10/28/2969945/28255/en/Evoke-Pharma-EVERSANA-Announce-Statistically-Significant-Improvement-in-Patient-Outcomes-for-GLP-1-users-with-Diabetic-Gastroparesis-using-GIMOTI.html